Vyera's research and development resources are devoted to identifying next-generation therapies for toxoplasmosis and other neglected parasitic infections – diseases with limited treatment options.

In Q1 of 2018, Vyera hopes to begin its first clinical trial to investigate the safety of TUR-006, a new molecule discovered and developed internally, for the treatment of toxoplasmosis.

Our Pipeline

Our pipeline is advancing with the support of a global team dedicated to exploring new ways to address disease.

View Our Current Pipeline

You are about to enter a site that is for US healthcare professionals only. By clicking "Confirm" below, you certify that you are a healthcare professional and that you wish to proceed to the Healthcare Professionals Only section of this site. Products or treatments described on this site are available in the US but may not be available in other countries.

I am a licensed healthcare professional and wish to proceed to the Healthcare Professionals section of this site.